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2 
Abstract 18 
Nine novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (FLQY, FQLGASPY, 19 
ILDKEGIDY, ILELA, LLQLEAIR, LPVP, LQALHQGQIV, MPVQA and SPVVPF) were 20 
identified in camel milk proteins hydrolysed with trypsin. This was achieved using a sequential 21 
approach combining liquid chromatography tandem mass spectrometry (LC-MS/MS), 22 
qualitative/quantitative structure activity relationship (QSAR) and confirmatory studies with 23 
synthetic peptides. The most potent camel milk protein-derived DPP-IV inhibitory peptides, 24 
LPVP and MPVQA, had DPP-IV half maximal inhibitory concentrations (IC50) of 87.0  3.2 and 25 
93.3  8.0 µM, respectively. DPP-IV inhibitory peptide sequences identified within camel and 26 
bovine milk protein hydrolysates generated under the same hydrolysis conditions differ. This 27 
was linked to differences in enzyme selectivity for peptide bond cleavage of camel and bovine 28 
milk proteins as well as dissimilarities in their amino acid sequences. Camel milk proteins 29 
contain novel DPP-IV inhibitory peptides which may play a role in the regulation of glycaemia 30 
in humans. 31 
 32 
 33 
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1 Introduction 36 
Milk from the one humped camel (Camelus dromedarius) is widely consumed in desert areas of 37 
Asia and Africa. Camel milk has been utilised for its biofunctional properties such as its 38 
purported beneficial immunomodulatory, antimicrobial, anticancer and antidiabetic activities 39 
(Abdel Gader & Alhaider, 2016; Agarwal et al., 2003; Hailu, Hansen, Seifu, Eshetu, Ipsen & 40 
Kappeler, 2016; Mati, Senoussi-Ghezali, Ahmed Zennia, Almi-Sebbane, El-Hatmi & Girardet, 41 
2016). Nongonierma, Paolella, Mudgil, Maqsood & FitzGerald (2017) recently reported on the 42 
ability of camel milk protein tryptic hydrolysates to inhibit dipeptidyl peptidase IV (DPP-IV) in 43 
vitro. Hydrolysed camel milk proteins may find applications in the management of type 2 44 
diabetes via their ability to inhibit DPP-IV. 45 
DPP-IV is a metabolic enzyme which can cleave and inactivate incretins (i.e., glucose-dependent 46 
insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and polypeptide YY (PYY)) 47 
(Andersen, Deacon & Holst, 2017). Inhibition of DPP-IV can lead to a longer duration of 48 
maintenance of the insulinotropic effect of the incretins. Food protein-derived peptides have 49 
been reported to inhibit DPP-IV in vitro and in vivo (for reviews, see: Lacroix & Li-Chan, 2016; 50 
Nongonierma & FitzGerald, 2016b). In silico digestion of camel s1-casein (CN) with trypsin 51 
and chymotrypsin suggested that known DPP-IV inhibitory dipeptides could be released (Erhardt 52 
et al., 2016). Known DPP-IV inhibitory peptides were identified in a gastrointestinal digest of 53 
camel milk proteins (Tagliazucchi, Shamsia & Conte, 2016) and tryptic camel milk protein 54 
hydrolysates (Nongonierma et al., 2017). However, camel milk protein hydrolysates may also 55 
contain DPP-IV inhibitory peptides which have not been previously reported in the literature. 56 
Identification of peptides within food protein hydrolysates generally involves several 57 
fractionation steps which can be relatively time-consuming and in certain instances may not be 58 
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suitable for the optimum separation of selected bioactive peptides or lead to a loss of beneficial 59 
peptide-peptide interactions (i.e., synergistic or additive effects) (Agyei, Ongkudon, Wei, Chan 60 
& Danquah, 2016; Nongonierma & FitzGerald, 2015; Panchaud, Affolter & Kussmann, 2012). 61 
Sagardia, Iloro, Elortza & Bald (2013) outlined the use of quantitative structure activity 62 
relationship (QSAR) modelling to aid in the discovery of novel angiotensin converting enzyme 63 
(ACE) inhibitory peptides within a complex mixture consisting of a water soluble extract of 64 
Idiazabal cheese. 65 
To date, most studies which have identified DPP-IV inhibitory peptides within complex mixtures 66 
have arisen as a result of different fractionation steps (Nongonierma & FitzGerald, 2016b). To 67 
our knowledge, the application of QSAR as an in silico tool to screen DPP-IV inhibitory peptides 68 
within complex camel milk protein hydrolysates has not been previously employed. The aim of 69 
this study was to identify novel DPP-IV inhibitory peptide sequences within camel milk protein 70 
hydrolysates. This was achieved by first selecting peptides possessing the features of DPP-IV 71 
inhibitory peptides. These consisted of peptides containing F/I/L/W at the N-terminus, P/A at 72 
position 2 and/or P at the C-terminus (Nongonierma & FitzGerald, 2013b, 2014a, 2016a; 73 
Tulipano, Faggi, Nardone, Cocchi & Caroli, 2015). The predicted DPP-IV inhibitory potential of 74 
these peptides was then determined using a previously developed QSAR model (Nongonierma & 75 
FitzGerald, 2016c). Selected synthetic peptide sequences, which were predicted to be potent 76 
DPP-IV inhibitors and stable to gastrointestinal enzymes, were then analysed for their in vitro 77 
DPP-IV inhibitory properties and their mode of inhibition was also studied. 78 
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2 Materials and methods 79 
2.1 Reagents 80 
High performance liquid chromatography (HPLC) grade water was from VWR (Dublin, Ireland). 81 
Tris(hydroxymethyl)aminomethane (TRIS), GP-pNA, L, diprotin A (IPI), porcine DPP-IV (≥ 10 82 
units mg
-1
 protein), MS grade water, acetonitrile (ACN) and formic acid (FA) were purchased 83 
from Sigma-Aldrich (Dublin, Ireland). Synthetic peptides (> 95% purity, AMPVQAVLP, FLQY, 84 
FQLGASPY, ILDKEGIDY, ILDKVGINY, ILELA, ILELAVVSPIQFR, LLQLEAIR, LPVP, 85 
LQALHQGQIV, MPVQA, VLPVP, SPVVPF and YPVEPF) were purchased from Genscript 86 
(Piscataway, NJ, USA). Skimmed freeze-dried milk (20% (w/w) protein) was obtained from the 87 
raw milk of one-humped Arabian camels (Camelus dromedarius) procured from the Al Ain 88 
Dairy farm (Al Ain, United Arab Emirates (UAE)) and bovine (Bos taurus) milk protein isolate 89 
(MPI, 86% (w/w) protein) was obtained from Kerry Ingredients (Listowel, Ireland). 90 
2.2 Enzymatic hydrolysis of camel milk proteins 91 
Camel milk protein hydrolysates were produced with a commercial trypsin preparation (PTN 92 
6.0S, Novozymes, Bagsvaerd, Denmark) as previously described in an earlier study 93 
(Nongonierma et al., 2017). Briefly, camel milk (2.5% (w protein/w)) was resuspended in 94 
distilled water and incubated for 60 min in a water bath (Lauda E100, Lauda Brinkmann, Lauda-95 
Königshofen, Germany) set at 50C. Subsequently, the pH was adjusted to 7.0 using 2 M NaOH 96 
(VWR). Temperature, enzyme to substrate ratio (E:S) and hydrolysis time were as defined in 97 
Supplementary Table S1. At the end of each reaction, the enzyme was heat inactivated (90°C, 20 98 
min) in a water bath. Two camel milk protein hydrolysates (H9 and H16), possessing potent 99 
DPP-IV inhibitory activity (DPP-IV half maximal inhibitory concentration (IC50) value of 0.52 100 
and 0.66 mg mL
-1
, respectively, Supplementary Table S1), were studied. In addition, one bovine 101 
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MPI hydrolysate (H17) made using the same hydrolysis conditions as H16 (DPP-IV IC50 value 102 
of 0.82 mg mL
-1
, Supplementary Table S1) was also studied. 103 
2.3 Simulated gastrointestinal digestion (SGID) of camel milk and camel milk protein 104 
hydrolysates 105 
Two samples, H9 and the camel milk were subjected to SGID following the protocol of Walsh et 106 
al. (2004). Briefly, samples were resuspended in distilled water to 2% (w protein equivalent/w) 107 
for 30 min at 37°C and the pH was adjusted to 2.0 using 1 M HCl (VWR). Hydrolysis with 108 
pepsin (E:S 2.5% (w/w), Biocatalysts, Cefn, Wales, UK) was carried out under pH regulation 109 
(2.0) with HCl (pH stat Titrando 843, Tiamo 1.4 Metrohm, Dublin, Ireland) for 90 min at 37°C. 110 
The peptic hydrolysate was heat inactivated (90°C, 20 min) and then brought to pH 7.5 using 1 111 
M NaOH and hydrolysed with Corolase PP (E:S 1% (w/w), AB Enzymes, Darmstadt, Germany) 112 
for 150 min at 37°C, pH 7.5 using a pH stat (Metrohm), to yield SGID_H9 or SGID_CM from 113 
H9 and camel milk, respectively. The reaction was terminated by heat treatment (90°C, 20 min). 114 
2.4 Peptide identification by liquid chromatography tandem mass spectrometry (LC-115 
MS/MS) 116 
Peptide identification was performed for the samples in H9, H16, H17, SGID_H9 and SGID_CM 117 
using LC-MS/MS as described previously (Nongonierma et al., 2017). Briefly, an ultra-HPLC 118 
(UHPLC) UltiMate 3000 (Dionex, Camberley, Surrey, UK) fitted with a security guard UHPLC 119 
C18 PEPTIDE (2.1 mm, Phenomenex, Cheshire, UK) and an Aeris Peptide XB-C18 column 120 
(150  2.1 mm, 1.7 μm, Phenomenex) was used for peptide separation at 25°C. The UHPLC was 121 
coupled to a quadrupole time-of-flight mass spectrometer (Q-TOF, Impact HD™, Bruker 122 
Daltonics GmbH, Bremen, Germany) using a 50-600 and 100-2500 m/z acquisition range. The 123 
MS was fitted with an electrospray ionisation (ESI) source used in positive ion mode. Data 124 
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acquisition was performed with Hystar software (Bruker Daltonics). Samples were resuspended 125 
in mobile phase A (0.1% FA in MS water) to a final concentration of 0.1 g L
-1 
and filtered with 126 
regenerated cellulose filters (Minisart® RC15, Sartorius, Goettingen, Germany). A sample 127 
volume of 5 (for ions ranging from 100-2500 m/z) and 10 µL (for ions ranging from 50 to 600 128 
m/z) was injected. Peptide identification was carried out with PEAKS Studio software (version 129 
7.5, Bioinformatics Solutions Inc., Waterloo, Canada) and its database search tools including 130 
PEAKS DE NOVO sequencing, PEAKS BD (database search), PEAKS PTM (post transitional 131 
modifications) and SPIDER (algorithm that matches sequence tags with errors to database 132 
sequences for the purpose of protein and peptide identification). The database used was 133 
UniProtKB/Swiss-Prot (http://www.uniprot.org), taxa Bos taurus and Camelus dromedarius. The 134 
false discovery rate (FDR), average local confidence (ALC) and MS/MS tolerance were set at 1, 135 
60% and 0.1 Da, respectively. In addition, selected synthetic peptides (ILDKEGIDY, 136 
ILDKVGINY, ILELA, LLQLEAIR, LPVP, MPVQA, SPVVPF and YPVEPF) were analysed 137 
using the same LC-MS/MS conditions in order to confirm the software identification. All other 138 
amino acid sequences detected using PEAKS Studio software were manually checked to verify 139 
the peptide’s fragmentation spectrum (as ion series continuity and major peaks identified as b or 140 
y ions). 141 
2.5 In silico analysis of peptides identified within the camel milk protein hydrolysates 142 
Peptides with known DPP-IV IC50 values had been identified earlier within H9, H16, H17, 143 
SGID_H9 and SGID_CM (Nongonierma et al., 2017). In this study, the search for other novel 144 
DPP-IV inhibitory peptides within the camel milk protein hydrolysates was conducted in a 145 
sequential manner. First, sequences obtained from DE NOVO and BD analysis of the 146 
hydrolysates (H9, H16, H17, SGID_H9 and SGID_CM) possessing the features of DPP-IV 147 
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inhibitory peptides were searched for in all samples. DPP-IV inhibitory peptide features include 148 
hydrophobic amino acids (F/I/L/W) at the N-terminus, P/A at position 2 and/or P at the C-149 
terminus (Nongonierma & FitzGerald, 2013b, 2014a, 2016a; Tulipano et al., 2015). In a second 150 
step, the DPP-IV inhibitory activity (IC50) of the peptides having DPP-IV inhibitory features was 151 
predicted using a QSAR model developed for DPP-IV inhibitory peptides (Nongonierma & 152 
FitzGerald, 2016c). The structural v-scale (v1 (van der Waals volume), v2 (net charge index) and 153 
v3 (hydrophobic parameter of side chains)) of Lin, Long, Bo, Wang & Wu (2008) was used for 154 
the amino acid descriptors. QSAR modelling was carried out using Matlab (version R2015b, 155 
MathWorks, Inc, Natick, MA, USA) as previously outlined (Nongonierma & FitzGerald, 2016c). 156 
Y = c + ∑ ∑ 𝑖,𝑗
𝑗
1 𝑁𝑖,𝑗
𝑖
1 + ∑ ∑ 𝑖,𝑗
𝑗
1 𝐶𝑖,𝑗
𝑖
1 +  ε      (Equation 1) 157 
 158 
With Y, the DPP-IV IC50 value; i: the N- or C- terminal position of the amino acid (1 or 2); j: the 159 
amino acid descriptor number (varying between 1 and 3);  and β: the coefficients of the model; 160 
c, and ε the constant and residual of the model, respectively. 161 
Peptides were ranked in order of predicted DPP-IV inhibitory potency. Rank 1 and 35 were 162 
attributed to the most and least potent DPP-IV inhibitory peptides, respectively (Table 1). 163 
Among the previous sequences, peptides which were stable to SGID (i.e., sequences identified 164 
both in H9 and SGID_H9) were selected and synthesised (Genscript) for further confirmatory 165 
studies. In addition, the location of candidate peptides within mature camel and bovine milk 166 
protein sequences was determined. The protein sequences (αs1-, αs2-, β- and κ-CN as well as -167 
lactoglobulin (-Lg) and -lactalbumin (-La)) were obtained from Uniprot. 168 
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2.6 DPP-IV inhibition assay 169 
The DPP-IV inhibition assay was carried out in triplicate as outlined earlier (Nongonierma & 170 
FitzGerald, 2013a). The peptides were dispersed in HPLC water at concentrations ranging from 171 
2.5 to 1000
 
µM (final concentration) and IPI, the positive control at final concentrations ranging 172 
from 37 × 10
-2
 to 37 µM. Essentially, 25L of sample was pipetted onto a 96-well microplate 173 
(Sarstedt, Dublin, Ireland) containing the reaction substrate, GP-pNA (final concentration 0.200 174 
mM). The reaction was initiated by the addition of DPP-IV (final concentration 0.0025 units mL
-
175 
1
). All reagents were diluted in 100 mM Tris-HCl buffer pH 8.0. The negative control consisted 176 
of 100 mM Tris-HCl buffer pH 8.0 and GP-pNA. The microplate was incubated at 37C for 60 177 
min in a microplate reader (Biotek Synergy HT, Winoosky, VT, USA) and the absorbance of the 178 
pNA released was monitored at 405 nm. The DPP-IV IC50 values were determined by plotting 179 
the percentage inhibition as a function of the test compound concentration. Each analysis was 180 
conducted in triplicate (n=3). 181 
2.7 Determination of the mode of inhibition of DPP-IV  182 
The mode of DPP-IV inhibition was assessed using the Lineweaver and Burk double reciprocal 183 
representation as previously described by Nongonierma & FitzGerald (2013a). Briefly, the most 184 
potent DPP-IV inhibitory peptides identified (ILDKEGIDY, ILDKVGINY, ILELA, 185 
LLQLEAIR, LPVP, MPVQA, SPVVPF and YPVEPF) were evaluated at 3 concentrations, i.e., 186 
their IC50 values divided by 4, 8 and 16. The positive control consisted of IPI also analysed at its 187 
IC50 value divided by 4, 8 and 16. The negative control consisted of samples containing no 188 
inhibitory peptides. The concentrations of GP-pNA ranged from 0.1 to 0.6 mM (final 189 
concentration). The absorbance at 405 nm was recorded for 30 min at 37C using a microplate 190 
reader (Biotek Synergy HT). Each sample was evaluated 4 times. 191 
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2.8 Peptide stability to DPP-IV 192 
Samples generated during the Lineweaver and Burk experiment (section 2.7) containing DPP-IV 193 
inhibitory peptides (ILDKEGIDY, ILDKVGINY, ILELA, IPI, LLQLEAIR, LPVP, MPVQA, 194 
SPVVPF and YPVEPF) at their IC50 values divided by 4 were also analysed by LC-MS/MS to 195 
check the stability of the peptides to hydrolysis by DPP-IV. At the end of the 30 min incubation 196 
period with DPP-IV and the reaction substrate (GP-pNA), the samples were heat inactivated for 197 
20 min at 90C in a water bath to terminate the reaction as these conditions were previously 198 
shown to inactivate DPP-IV (Nongonierma & FitzGerald, 2014b). The samples (5 µL) were 199 
diluted in 200 µL mobile phase A (0.1% FA in MS water). The negative control consisted of 200 
peptides which were not incubated with DPP-IV and were injected at the same concentration as 201 
the test peptides. The peptide composition of the samples was determined using the methods 202 
outlined in section 2.4, i.e., injection in a UHPLC (Dionex) coupled to a Q-TOF (Bruker 203 
Daltonics GmbH) using a 50-2500 m/z acquisition range. An injection volume of 2 µL was used 204 
and a solvent delay of 5 min was applied. 205 
2.9 Statistical analysis  206 
A one-way analysis of variance (ANOVA) at a significance level of p < 0.05 was employed to 207 
study differences between mean DPP-IV IC50 values. ANOVA was followed by a post-hoc 208 
Student Newman Keuls test (p < 0.05) conducted with SPSS (version 22, SPSS Inc., Chicago, 209 
IL, USA). 210 
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3 Results and discussion 211 
3.1 In silico analysis of camel milk peptides 212 
Numerous peptides (between 727 (H9) and 1903 (H17)) sequences were identified by LC-213 
MS/MS within the camel and bovine milk protein hydrolysates using DE NOVO and DB 214 
analysis. These peptides were first assessed for the presence of typical DPP-IV inhibitory 215 
features, i.e., hydrophobic amino acids (F/I/L/W) at the N-terminus, P/A at position 2 and/or P at 216 
the C-terminus (Nongonierma & FitzGerald, 2013b, 2014a, 2016a; Tulipano et al., 2015). The 217 
predicted DPP-IV inhibitory activity of the selected peptides was then determined using QSAR 218 
(Nongonierma & FitzGerald, 2016c). The selected peptides identified within H9, H16, H17, 219 
SGID_H9 and SGID_CM are shown in Table 1. As already outlined, the QSAR model employed 220 
does not accurately provide a DPP-IV IC50 value and furthermore the model is only applicable to 221 
competitive DPP-IV inhibitory peptides. Therefore, results obtained by QSAR analysis only 222 
allows ranking of peptides which are competitive inhibitors of DPP-IV (Nongonierma & 223 
FitzGerald, 2016c). Consequently, the mode of DPP-IV inhibition of the peptides also needs to 224 
be determined. In total, 35 camel milk protein-derived peptides possessing DPP-IV inhibitory 225 
peptide features and predicted to be stable to SGID were selected (Table 1). 226 
Most of the peptides selected for their potential to act as DPP-IV inhibitors originate from CNs, 227 
this may arise from the fact that CNs are the most abundant protein components of camel milk, 228 
representing ~ 74% of the total protein content, with -CN representing 65% of the total CN 229 
fraction (Hailu et al., 2016). A number of these peptides (12) exist both within camel and bovine 230 
milk protein sequences (Table 1). These were generally released in the camel milk sample (H16) 231 
and not the bovine milk sample (H17) during hydrolysis. However, most of the peptides 232 
identified (23) within the camel milk protein hydrolysates were unique to camel milk proteins 233 
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(Table 1). This was attributed to amino acid sequence differences between the proteins of the 2 234 
species. 235 
Of the peptides identified in Table 1, most dipeptides had already been studied for their in vitro 236 
DPP-IV inhibitory activity. This was the case for LT, LV, VI, IR and VL which were reported to 237 
inhibit DPP-IV by 23.7, 24.8, 30.4, 39.4 and 52.2% when analysed at 100 µM. While the other 238 
dipeptides (i.e., FR, FY, LE, IE, IT, IV and LY) when analysed in the same study at 100 µM 239 
inhibited DPP-IV by < 5% (Lan, Ito, Ohno, Motoyama, Ito & Kawarasaki, 2015). Three 240 
dipeptides (LR/IR, LT/IT and LY/IY) were identified within H17, the bovine milk protein 241 
hydrolysate. Given that the objective of the study was the identification of novel peptide 242 
sequences having DPP-IV inhibitory activity, it was decided to focus on peptides  3 amino acid 243 
residues which were also identified following SGID of H9 (SGID_H9) herein. 244 
Eleven peptides (AMPVQAVLP, FLQY, FQLGASPY, ILDKEGIDY, ILELA, 245 
ILELAVVSPIQFR, LLQLEAIR, LPVP, LQALHQGQIV, MPVQA and VLPVP) originating 246 
from camel milk proteins were identified within H9, H16, SGID_H9 and SGID_CM. The fully 247 
annotated MS/MS spectra for LPVP and MPVQA are illustrated in Supplementary Fig. S1. 248 
These peptides were synthetized and analysed for their in vitro DPP-IV inhibitory properties 249 
(Table 2). The tryptic camel milk protein hydrolysate (H16), which was produced under the same 250 
conditions (40C, 1.8% E:S and 218 min) as H17, the bovine milk protein hydrolysate, was 251 
previously shown to be a more potent DPP-IV inhibitory hydrolysate than H17 (Nongonierma et 252 
al., 2017). Therefore, to better understand the role of milk species (camel vs. bovine) on the 253 
DPP-IV inhibitory activity, 2 specific bovine milk peptides (ILDKVGINY (-La (f95-103)) and 254 
YPVEPF (-CN (f114-119))) identified within H17 in our previous work (Nongonierma et al., 255 
2017) and their corresponding homologous camel milk peptides (ILDKEGIDY (α-La (f95-103)) 256 
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and SPVVPF (-CN (f115-120)) identified in particular in SGID_H9) were further studied. 257 
Three additional peptides (ILDKVGINY, YPVEPF and SPVVPF) were synthetized. The bovine 258 
milk protein-derived peptides, ILDKVGINY and YPVEPF, are known DPP-IV inhibitors having 259 
IC50 values of 236 µM (Lacroix & Li-Chan, 2014) and 124.7 µM (Nongonierma & FitzGerald, 260 
2016c), respectively. In total, 14 peptides were experimentally assessed for their DPP-IV 261 
inhibitory activity (Table 2). 262 
3.2 In vitro DPP-IV inhibitory properties of camel milk peptides 263 
The 14 peptides selected for synthesis were first evaluated for their ability to inhibit DPP-IV at 264 
1000 µM (Table 2). One of the peptides (ILELAVVSPIQFR) could not be studied due to its poor 265 
aqueous solubility. The other peptides yielded various extents of DPP-IV inhibitory activity 266 
ranging from -11.8  3.3 to 95.0  3.0% for VLPVP and YPVEPF, respectively. The DPP-IV 267 
IC50 value of the 8 most potent peptides (ILDKEGIDY, ILDKVGINY, ILELA, LLQLEAIR, 268 
LPVP, MPVQA, SPVVPF and YPVEPF), causing > 50% DPP-IV inhibition, when tested at 269 
1000 µM, was then determined. Their DPP-IV IC50 values ranged from 87.0  3.2
 
to 721.1  270 
46.3
 
µM for LPVP and ILELA, respectively (Table 2). The overall outcome was that novel 271 
peptide sequences which have not previously been reported for their DPP-IV inhibitory 272 
properties were identified for the first time in camel milk protein hydrolysates within this study. 273 
The 2 most potent peptides studied, LPVP and MPVQA, had DPP-IV IC50 values of the same 274 
order (87.0  3.2 and 93.3  8.0 µM (p > 0.05), respectively). These peptides have a potency that 275 
is lower than that of IPI, the most potent peptide identified, to date, having a DPP-IV IC50 value 276 
of 3.2 µM (Umezawa, Aoyagi, Ogawa, Naganawa, Hamada & Takeuchi, 1984). Other more 277 
potent DPP-IV inhibitory peptides originating from camel and bovine milk proteins have been 278 
reported in the literature. For instance, WK, WL and LPVPQ, having DPP-IV IC50 values of, 279 
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40.6, 43.6 and 43.7, respectively, were previously identified within the camel milk protein 280 
hydrolysates H9 and H16 (Nongonierma et al., 2017). Potent peptides such as LKPTPEGDLE 281 
(Lacroix, Meng, Cheung & Li-Chan, 2016), IPAVF (Silveira, Martínez-Maqueda, Recio & 282 
Hernández-Ledesma, 2013), LKPTPEGDL (Lacroix & Li-Chan, 2014) and LPQNIPPL 283 
(Uenishi, Kabuki, Seto, Serizawa & Nakajima, 2012), identified within bovine milk protein 284 
hydrolysates/cheese, had DPP-IV IC50 values of 42 and 44.7, 45 and 46 µM, respectively. 285 
LPVP is present both in camel and bovine β-CN (Fig. 1). However, surprisingly, it was only 286 
identified within H16 the camel milk protein hydrolysate but not in H17, the bovine milk protein 287 
hydrolysate produced using the same hydrolysis conditions as H16. Nevertheless, larger 288 
fragments containing LPVP, i.e., VLPVPQ and VLPVPQK, were identified both in H17 and 289 
H16 (data not shown). The sequence where LPVP is located within β-CN is conserved between 290 
the 2 species (Fig. 1). In both camel and bovine β-CN the amino acids upstream (V) and 291 
downstream (Q) of LPVP are the same. The reason why this peptide may be released from camel 292 
but not bovine β-CN is not fully understood. The release of LPVP from camel β-CN does not 293 
appear to be a random phenomenon as it was also identified in H9, another camel milk protein 294 
hydrolysate generated with PTN 6.0S using different hydrolysis conditions (Table 1 and 295 
Supplementary Table S1). 296 
In a previous study, selective release from camel (H16) but not bovine (H17) β-CN, was 297 
observed for LPLPL and LPVPQ (Fig. 1), 2 DPP-IV inhibitory peptides (Nongonierma et al., 298 
2017). LPVPQ is adjacent to a non-conserved area of β-CN with Q, the downstream amino acid 299 
in camel β-CN, being substituted by K in bovine β-CN while the upstream amino acid (V) is the 300 
same in both species (Fig. 1). For LPLPL, the amino acids upstream (H) and downstream (L) of 301 
the peptide are the same in camel and bovine β-CN (Fig. 1). In bovine β-CN, the LC-MS/MS 302 
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results indicated that LPLPL was partly degraded to a shorter fragment corresponding to LPL 303 
(Fig. 1). These results seem to indicate that the enzyme selectivity towards substrates containing 304 
similar peptide bond varies between camel and bovine milk proteins. This may arise from the 305 
fact that camel milk proteins have been reported to be digested in a different manner by 306 
gastrointestinal enzymes compared to bovine milk proteins. Camel whey proteins were reported 307 
to be less digested by chymotrypsin and trypsin than bovine whey proteins. On the contrary, 308 
camel CNs were more digested by trypsin/chymotrypsin than bovine CNs (Salami et al., 2008). 309 
These findings may be consistent with the observation that DPP-IV inhibitory sequences which 310 
are present in both camel and bovine milk β-CN are not released to the same extent in the camel 311 
(H16) and the bovine milk protein (H17) hydrolysates (Fig. 1). To our knowledge, this is the first 312 
time that species dependent substrates (camel vs. bovine) have been clearly shown to affect the 313 
selectivity of peptide bond cleavage during enzymatic digestion of milk proteins. This in turn 314 
may play an important role in releasing peptides possessing specific bioactivity. 315 
MPVQA is only present within camel β-CN and not within bovine β-CN (Fig. 1). Similar to 316 
LPVP this peptide appears to arise as a result of a non-specific cleavage of β-CN or due to the 317 
occurrence of side activities within the enzyme preparation (PTN 6.0S). According to their 318 
cleavage specificity, trypsin and chymotrypsin, cleave at the C-terminal side of R/K and bulky 319 
hydrophobic amino acids (F/K/W/Y), respectively (Godfrey, 1996). Several peptides were 320 
identified within the tryptic camel milk protein hydrolysates (H9 and H16, Table 1), which did 321 
not agree with the cleavage specificity of trypsin and chymotrypsin. These peptides possessed an 322 
A/P/V (i.e., LPVP, LQALHQGQIV, MPVQA, NFLPPLQP, VAWYYPPQV and VLPVP) at 323 
their C-terminus. Their release may be due to the presence of P-specific exo/endopeptidases, 324 
pancreatic elastase which cleaves at the C-terminal side of A/V (Bode, Meyer Jr & Powers, 325 
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1989; Godfrey, 1996) or to non-specific cleavages of the camel milk proteins. It was previously 326 
demonstrated that PTN 3.0S, a porcine trypsin preparation manufactured by the same supplier 327 
(Novozymes), contains trypsin, chymotrypsin and pancreatic elastase along with a range of 328 
dipeptidyl-, carboxy- and amino-peptidases (Mullally, O'Callaghan, FitzGerald, Donnelly & 329 
Dalton, 1994). Pancreatic elastase may also be present as a side activity of PTN 6.0S which is 330 
extracted from porcine pancreas. Pancreatic elastase has previously been employed to generate 331 
DPP-IV inhibitory bovine -La and -Lg hydrolysates (Le Maux, Nongonierma & FitzGerald, 332 
2017; Nongonierma, Le Maux, Hamayon & FitzGerald, 2016). However, the DPP-IV IC50 value 333 
(ranging from 1.20 to 2.15 and 1.02 to 1.49 mg mL
-1
 for -La and -Lg hydrolysates, 334 
respectively) of these hydrolysates was higher than that of H17 (0.82 mg mL
-1
). 335 
Interestingly, amongst the 5 most potent (< 300 µM) DPP-IV inhibitory peptides (LPVP, 336 
MPVQA, YPVEPF, LLQLEAIR and SPVVPF), 4 peptides (LPVP, MPVQA, YPVEPF and 337 
SPVVPF) possess the structure of preferred DPP-IV inhibitory substrates, i.e., with P at position 338 
2 in the peptide (Table 2). Peptides possessing a P at the penultimate position have been shown 339 
to be able to inhibit DPP-IV via a substrate-type inhibition. Substrate-type inhibitory peptides 340 
bind to the active site where they are subsequently degraded into shorter fragments 341 
(Nongonierma & FitzGerald, 2014b; Rahfeld, Schierborn, Hartrodt, Neubert & Heins, 1991). 342 
This interaction with the active site is responsible for the inhibition of DPP-IV. The presence of 343 
P at position 2 is important for DPP-IV inhibition as the activity of LPVP and MPVQA was 344 
absent when these sequences were present as the precursor peptides VLPVP and AMPVQAVLP, 345 
respectively, where both had DPP-IV IC50 values > 1000 µM (Table 2). 346 
As already outlined, several known DPP-IV inhibitory peptides have already been identified 347 
within the camel milk protein hydrolysates H9, H16, SGID_H9 and SGID_CM (Nongonierma et 348 
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al., 2017). The DPP-IV inhibitory peptides identified previously in camel milk protein 349 
hydrolysates and for which an IC50 value have been determined in the literature or in this study 350 
are depicted on the sequence of camel β-CN (Fig. 1). The most potent DPP-IV inhibitory 351 
peptides (DPP-IV IC50 value < 300 µM) previously identified in the camel milk samples were all 352 
dipeptides (i.e., HL, LA, LL, WK, WL and WY) with the exception of LPVPQ (Nongonierma et 353 
al., 2017) which had a DPP-IV IC50 value of 43.7 µM (Nongonierma & FitzGerald, 2016c). 354 
There was a twofold difference in magnitude between the DPP-IV IC50 value of LPVPQ and 355 
LPVP. This result shows that the addition of a Q at the C-terminal side of LPVP (IC50: 87.0 µM) 356 
has a major effect on increasing the DPP-IV inhibitory potency. The reason for this may be 357 
linked to the fact that LPVPQ contains 2 internally located P residues at positions 2 and 4 while 358 
LPVP only contains 1 internal P at position 2. LPVPQ is also a substrate of DPP-IV which can 359 
be cleaved into LP and VPQ. Interestingly, VPQ may be further cleaved by DPP-IV as it also 360 
displays the features of preferred DPP-IV inhibitory peptide substrates. In an earlier study, 361 
LPLPL and LPYPY, 2 DPP-IV inhibitory peptides also containing 2 internally located P residues 362 
at positions 2 and 4 were shown to be cleaved at the C-terminal side of the 2 P residues when 363 
incubated with DPP-IV (Nongonierma & FitzGerald, 2014b). The fact that a substrate of DPP-IV 364 
can be a source to release more inhibitors may in turn modify the overall DPP-IV inhibitory 365 
activity. 366 
3.3 In vitro DPP-IV inhibitory properties of homologous camel and bovine milk peptides 367 
The DPP-IV IC50 values of the bovine milk peptides ILDKVGINY and YPVEPF (321.5  29.5
 
368 
and 138.0  15.3 µM, respectively, Table 2) were of the same order as values in the literature. 369 
Previous studies have reported the DPP-IV IC50 values of ILDKVGINY and YPVEPF, i.e., 263 370 
(Lacroix & Li-Chan, 2014) and 125 µM (Nongonierma & FitzGerald, 2016c), respectively. The 371 
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DPP-IV IC50 values of the 2 homologous peptides ILDKEGIDY and ILDKVGINY (347.8  42.8
 
372 
and 321.5  29.5 µM, respectively, Table 2) were not significantly different (p > 0.05). In 373 
contrast, significant differences (p < 0.05) were seen for the DPP-IV IC50 values of the 2 374 
homologous peptides SPVVPF and YPVEPF (214.1  16.7 and 138.0  15.3 µM, respectively, 375 
Table 2). QSAR analysis has previously indicated that the first 2 N-terminal amino acids of 376 
peptides govern their DPP-IV inhibitory properties while other amino acids did not appear to 377 
play such an important role in DPP-IV inhibition (Nongonierma & FitzGerald, 2016a, 2016c). 378 
These earlier findings were confirmed by the results from the homologous peptides studied 379 
herein. Differences in the N-terminal amino acids of SPVVPF and YPVEPF may contribute to 380 
the observed variation in their DPP-IV IC50 values. On the other hand, the first 2 amino acids of 381 
ILDKEGIDY and ILDKVGINY were the same (i.e., IL). This similarity in end N-terminal 382 
sequence may have contributed to their identical DPP-IV IC50 values (p > 0.05). The fifth and 383 
eighth amino acids of these peptides, E and D, were substituted with a V and N in the bovine 384 
homologue, but this had no impact on the DPP-IV inhibition exerted by the peptides. The first 2 385 
N-terminal amino acids are, however, not the only residues which can contribute to the DPP-IV 386 
inhibitory properties of peptides. In fact, another peptide analysed in this study, ILELA, 387 
possessed the same IL- N-terminal sequence as ILDKEGIDY/ILDKVGINY. However, the DPP-388 
IV IC50 value of ILELA (721.1  46.3 µM, Table 2) was ~ 2 fold higher than that of 389 
ILDKEGIDY/ILDKVGINY. Tulipano et al. (2015) analysed the amino acid sequences which 390 
were frequently identified in potent DPP-IV inhibitory peptides and found that branched chain 391 
amino acids (BCAAs) were often present at positions 1 and 2 of potent DPP-IV inhibitory 392 
peptides which is consistent with the bioactivity observed for ILDKEGIDY/ILDKVGINY and 393 
ILELA. In addition, they reported that the third amino acid present in potent peptides was often 394 
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an aliphatic residue or a BCAA. The third amino acid of ILDKEGIDY/ILDKVGINY and ILELA 395 
consists of an acidic (negatively charged side chain) amino acid (D and E, respectively). The 396 
fourth amino acid of the peptides together with their physicochemical properties (i.e., 397 
hydrophobicity, charge and steric hindrance) may also contribute to the differences seen in the 398 
bioactivity of those 3 peptides. 399 
To our knowledge, homologous peptides arising from camel and bovine milk proteins have not 400 
previously been studied in the context of their bioactive properties. The results herein show that 401 
depending on the position of the amino acid substitution in the peptide sequence, the DPP-IV 402 
inhibitory properties of the peptide may (e.g., SPVVPF vs. YPVEPF) or not (e.g., ILDKEGIDY 403 
vs. ILDKVGINY) be modified. 404 
An in silico analysis was previously performed to predict the DPP-IV inhibitory potency index 405 
(PI) of the major individual camel and bovine milk proteins (Nongonierma et al., 2017). It 406 
showed that certain individual camel milk proteins (i.e., αs2- and β-CN) displayed a higher DPP-407 
IV PI (based on known DPP-IV inhibitory peptides) compared to bovine milk protein 408 
equivalents. These dissimilarities were attributed to differences in sequence homology between 409 
individual proteins of both species. Sequence homology varying from 46.6 and 69.7% were 410 
reported for αs1-CN and -La, respectively (Nongonierma et al., 2017). The occurrence of DPP-411 
IV inhibitory peptides within the non-conserved regions of these proteins may therefore also 412 
explain the release of selected peptides within camel compared to bovine milk proteins. 413 
3.4 Stability of the peptides to incubation with DPP-IV 414 
Six of the peptides analysed (IPI, ILDKEGIDY, ILDKVGINY, ILELA, LLQLEAIR and LPVP) 415 
were not degraded during 30 min incubation with DPP-IV at 37C. In contrast, 3 peptides 416 
(MPVQA, SPVVPF and YPVEPF) were cleaved during incubation with DPP-IV. The LC-417 
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MS/MS data obtained within the acquisition range 50-2500 m/z for IPI, LPVP, YPVEPF and 418 
SPVVPF is presented in Fig. 2. All 4 peptides possess the structure of preferred DPP-IV 419 
substrates. As expected, YPVEPF and SPVVPF were cleaved by DPP-IV at the C-terminal side 420 
of the penultimate P residue. The expected products of this reaction (i.e, YP and VEPF) were 421 
identified for YPVEPF, while for SPVVPF only VVPF was identified (the expected reaction 422 
products are SP and VVPF, Fig. 2). In contrast, when IPI and LPVP were incubated with DPP-423 
IV, no peptide degradation was observed (Fig. 2), which may be attributed to the possibility that 424 
the degradation products (I, PI, LP and VP) were below the limit of detection of the MS. The 425 
results for IPI are in contrast with the study of Rahfeld et al. (1991) which reported a degradation 426 
of IPI in IP and I upon incubation with DPP-IV. However, the results herein agree with an earlier 427 
study where < 8% degradation of IPI by DPP-IV could be detected for a longer incubation time 428 
of 18 h at 37C in the absence of GP-pNA (Nongonierma & FitzGerald, 2014b). 429 
During incubation of MPVQA with DPP-IV, VQA but not MP was detected (data not shown). 430 
Interestingly, another peak corresponding to the oxidised peptide M(+16)PVQA was identified, 431 
but only in the sample which was incubated at 37C with DPP-IV and GP-pNA. The oxidation 432 
may have occurred as a result of heating the peptide at 37C for 30 min. The effect of oxidation 433 
on the DPP-IV inhibitory properties of MPVQA is unknown as the specific contribution of 434 
M(+16)PVQA to DPP-IV inhibition was not determined within the present study. Other studies 435 
have evaluated the role of post-translational modifications such as T phosphorylation (WT 436 
(Nongonierma & FitzGerald, 2013c)) and M oxidation (GPM (Jin, Yan, Yu & Qi, 2015)), which 437 
both resulted in a significant decrease in the DPP-IV IC50 value. 438 
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3.5 Mode of DPP-IV inhibition of camel milk peptides 439 
The Lineweaver and Burke reciprocal representation of the DPP-IV mode of inhibition of the 440 
peptides is shown in Fig. 3. Of the 8 peptides evaluated, 4 (ILDKEGIDY, ILDKVGINY, 441 
SPVVPF and YPVEPF) displayed a mixed-type inhibition while 4 (ILELA, LLQLEAIR, LPVP 442 
and MPVQA) were competitive inhibitors of DPP-IV (Fig. 3 and Table 2). 443 
Peptides possessing the structure of preferred DPP-IV substrates (i.e., P/A residues at position 2) 444 
are generally thought to behave as competitive inhibitors of DPP-IV as they bind to its active site 445 
(Rahfeld et al., 1991). However, this was not the case for SPVVPF and YPVEPF herein, which 446 
were mixed-type inhibitors of DPP-IV. Similar results have already been obtained in earlier 447 
studies where peptides possessing a P at position 2 were also identified as mixed-type inhibitors 448 
of DPP-IV (Nongonierma & FitzGerald, 2016c). The reason for this mode of inhibition is 449 
unclear. These DPP-IV substrates were hydrolysed to shorter entities (Fig. 2), which may also be 450 
DPP-IV inhibitors displaying a different mode of inhibition. This in turn may interfere with the 451 
evaluation of the kinetics parameters of the original peptide. The DPP-IV inhibition activity of 452 
some of the products arising from hydrolysis of these peptides by DPP-IV has been shown 453 
earlier for SP and YP (Hatanaka et al., 2012). However, their mode of inhibition was not 454 
determined. 455 
The findings described herein are relevant for the valorisation and broader utilisation of camel 456 
milk as they highlight novel potential nutritional properties of its constitutive proteins. Some of 457 
the camel milk protein-derived DPP-IV inhibitory peptides identified herein are not found within 458 
the primary sequence of bovine milk proteins (FLQY, FQLGASPY, ILDKEGIDY, ILELA, 459 
LLQLEAIR, LQALHQGQIV and MPVQA) or could only be identified in camel but not bovine 460 
(LPVP) milk protein hydrolysates. This suggests that hydrolysed camel milk proteins have 461 
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potential for the release of unique DPP-IV inhibitory peptides. A recent study has demonstrated 462 
that the in vitro SGID protocol developed within the INFOGEST network was able to mimic the 463 
release of peptides during the gastrointestinal digestion of bovine milk proteins in humans 464 
(Sanchón et al., 2018). While a different SGID protocol was used herein, the novel peptides 465 
released herein may be relevant to human health. Ultimately, evaluation of camel milk protein 466 
hydrolysates in human intervention studies is required to study their potential to play a role in the 467 
regulation of glycaemia. 468 
4 Conclusions 469 
Using a sequential in silico approach, it was possible to identify novel DPP-IV inhibitory 470 
peptides within camel milk protein hydrolysates. In particular, 2 potent DPP-IV inhibitory 471 
peptides, LPVP and MPVQA, having DPP-IV IC50 values < 100 µM, were identified for the first 472 
time in camel milk protein hydrolysates. Selected DPP-IV inhibitory peptides (e.g., of LPVP, 473 
LPLPL and LPVPQ) which are present within conserved regions of -CN could only be 474 
identified within camel but not in bovine milk protein hydrolysates. This may indicate that the 475 
selectivity for cleavage of the peptide bonds located upstream and downstream of the sequences 476 
is dependent on the milk species, which may in turn be linked to the differential digestibility of 477 
camel and bovine milk proteins by gastrointestinal enzymes. Homologous peptides within camel 478 
and bovine milk proteins have been studied for the first time in respect to their DPP-IV 479 
inhibition. Some amino acid substitutions in peptide sequences did not impact on the DPP-IV 480 
inhibitory properties while other did. The different levels of homology between camel and 481 
bovine milk proteins may be responsible for the variations observed in the DPP-IV inhibitory 482 
properties of camel (H16) and bovine (H17) milk tryptic hydrolysates. It was demonstrated 483 
DOI: 10.1016/j.foodchem.2017.10.033 
23 
within this study that camel milk proteins can yield unique DPP-IV inhibitory peptides which 484 
differ from those released from bovine milk proteins. While intact camel milk has already been 485 
identified for its in vivo antidiabetic properties owing to the presence of insulin and insulin-like 486 
components, hydrolysed camel milk proteins may also yield antidiabetic properties in humans 487 
through a different mechanism of action involving the inhibition of DPP-IV and the incretin 488 
effect. 489 
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Table 1. Peptides possessing the typical features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides which were identified within camel (H9 628 
and H16) and bovine (H17) milk protein hydrolysates, and the simulated gastrointestinal digestion (SGID) of H9 (SGID_H9) and of camel milk 629 
(SGID_CM). 630 
Peptide sequence
1
 Peptides identified by LC-MS/MS
3
: DPP-IV 
inhibitory 
ranking
4
 
Peptide fragment
5
 
H9 H16H17 SGID_H9 SGID_CM bovine milk camel milk 
AMPVQAVLP   nd   6 - β-CN (f185-193) 
FHMSG nd nd nd   26 - α-La (f31-35) 
FKIEEQQQTEDEQQDKI nd nd nd   1 - β-CN (f34-50) 
FKIEEQQQTEDEQQDKIY   nd nd nd 30 - β-CN (f34-51) 
FLPPLQPAV nd nd nd   16 - β-CN (f76-84) 
FLQY   nd   11 - αs2-CN (f71-74) 
FQLGASPY   nd   28 - αs1-CN (f168-175) 
FR
2
 nd nd nd  nd 32 αs1-CN (f150-151), α-
La (f9-10) 
αs1-CN (f39-40) 
FY
2
   nd  nd 29 diverse αs2-CN (f65-66), κ-
CN (f67-79) 
IAHPSSY   nd nd nd 12 - αs1-CN (f188-194) 
ILDKEGIDY   nd   22 - α-La (f95-103) 
ILELA   nd   21 - αs1-CN (f28-32) 
ILELAVVSPIQFR   nd  nd 31 - αs1-CN (f28-40) 
LE
2
/IE
2
   nd   5 diverse diverse 
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Peptide sequence
1
 Peptides identified by LC-MS/MS
3
: DPP-IV 
inhibitory 
ranking
4
 
Peptide fragment
5
 
H9 H16H17 SGID_H9 SGID_CM bovine milk camel milk 
LEELHR   nd nd nd 27 - αs1-CN (f97-102) 
LLQLEAIR   nd   33 - αs1-CN (f108-115) 
LMY   nd nd nd 13 - β-CN (f144-146) 
LPVP   nd  nd 2 β-CN (f171-174) β-CN (f172-175) 
LQALHQGQIV  nd nd   34 - αs2-CN (f75-84) 
LQLEAIR   nd nd nd 35 - αs1-CN (f109-115) 
LR/IR
2
      23 diverse diverse 
LSSHP nd nd nd   3 - αs1-CN (f125-129) 
LT
2
/IT
2
 nd nd    24 diverse diverse 
LV
2
/IV
2
/VL
2
/VI
2
 nd nd nd   25 diverse diverse 
LVY   nd nd nd 10 β-CN (f58-60) β-CN (f59-61) 
LY
2
/IY      14 αs2-CN (f99-100), β-
CN (f192-193) 
diverse 
MPVQA   nd   20 - β-CN (f186-190) 
NFLPPLQP nd  nd nd nd 8 - β-CN (f75-82) 
VAWYYPPQV nd  nd   17 - αs1-CN (f176-184) 
VLP/VIP nd nd nd   7 β-CN (f170-172), αs2-
CN (f200-202) 
β-CN (f171-173), β-
CN (f191-193), κ-
CN (f124-126) 
VLPVP   nd   4 β-CN (f170-174) β-CN (f171-175) 
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Peptide sequence
1
 Peptides identified by LC-MS/MS
3
: DPP-IV 
inhibitory 
ranking
4
 
Peptide fragment
5
 
H9 H16H17 SGID_H9 SGID_CM bovine milk camel milk 
VPYPQR   nd nd nd 15 β-CN (f178-183) β-CN (f179-184) 
YPLR   nd nd nd 19 - αs1-CN (f4-7) 
YPPQVMQY   nd nd nd 9 - αs1-CN (f180-187) 
YPSYGINYY   nd nd nd 18 - κ-CN (f35-43) 
1
Peptide sequences abbreviated with the one letter amino acid code. Peptides in bold were selected for further investigation for their in vitro DPP-IV inhibitory activity. 631 
2
Peptides previously tested for their in vitro DPP-IV inhibition at 100 µM by Lan et al. (2015). 632 
3
SGID samples were obtained by sequential digestion of H9 or camel milk with pepsin then Corolase PP hydrolysis as previously described in Walsh et al. (2004); nd: not 633 
detected; : peptide detected by LC-MS/MS in the sample. 634 
4
DPP-IV inhibitory ranking in order of predicted DPP-IV inhibitory potency, i.e., rank 1 was attributed to the peptide predicted to be the most potent and rank 35 to the peptide 635 
predicted to be the least potent. 636 
5
Peptide fragment in the mature protein sequence; -La: -Lactalbumin; -Lg: -lactoglobulin; CN: casein; diverse: peptide sequence detected in  3 different fragments. 637 
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Table 2. Dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) of camel milk protein derived peptides identified within 638 
tryptic digests of camel milk proteins (H9 and H16), the simulated gastrointestinal digests (SGID) of H9 and the SGID of camel milk and 639 
homologous peptides from bovine milk proteins. 640 
Peptide sequence Molecular mass 
(Da) 
Peptide size DPP-IV inhibition at 
1000 µM
2 
(% ) 
DPP-IV IC50
2,3 
(µM) 
Mode of inhibition
4
 
AMPVQAVLP 925.2 9 3.8  2.8 > 1000 nd 
FLQY 569.7 4 40.8  5.3 > 1000 nd 
FQLGASPY 882.0 8 14.1  5.6 > 1000 nd 
ILDKEGIDY 1065.2 9 79.0  6.6 347.8  42.8e mixed-type 
ILDKVGINY
1
 1034.0 9 78.8  5.5 321.5  29.5e mixed-type 
ILELA 557.7 5 59.1  2.8 721.1  46.3f competitive 
ILELAVVSPIQFR 1484.8 13 non measurable  non measurable nd 
LLQLEAIR 955.2 8 83.6  4.6 177.8  22.2c competitive 
LPVP 424.5 4 93.3  3.6 87.0  3.2a competitive 
LQALHQGQIV 1106.3 10 27.2  5.6 > 1000 nd 
MPVQA 544.7 5 94.0  1.1 93.3  8.0a competitive 
VLPVP 523.7 5 -11.8  3.3 > 1000 nd 
SPVVPF 644.8 6 88.3  1.5 214.1  16.7d mixed-type 
YPVEPF
1
 750.9 6 95.0  3.0 138.0  15.3b mixed-type 
1
Homologous peptide from bovine milk proteins
 641 
2
Mean  SD (n=3). 642 
3
The IC50 value of the positive control IPI was 4.86 ± 0.57 µM. Values with different superscript letters are significantly different p < 0.05. 643 
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4
The mode of DPP-IV inhibition was determined using the Lineweaver and Burk double reciprocal representation (Nongonierma & FitzGerald, 2016c). nd: not determined. The 644 
mode of inhibition of IPI was competitive.  645 
 646 
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Figure captions 647 
 648 
Figure 1. Dipeptidyl peptidase IV (DPP-IV) inhibitory peptides originating from camel -casein 649 
(-CN) which were identified in the camel milk protein hydrolysates (H9, H16, SGID_H9 and 650 
SGID_CM) in this study (represented by a green line under the protein sequence) and in a 651 
previous study (Nongonierma et al., 2017) (represented by a blue line under the protein 652 
sequence). The location of these peptides is also represented for the bovine -CN sequence. 653 
DPP-IV inhibitory peptides identified in the camel (H16) and bovine milk protein hydrolysates 654 
(H17) are boxed. 655 
 656 
Figure 2. Extracted ion chromatogram of the ultra-high performance liquid chromatography 657 
(UHPLC) tandem mass spectrometry (MS/MS) profile of (A) IPI, (B) LPVP, (C) YPVEPF and 658 
(D) SPVVPF at 1/4 of their half maximal inhibitory concentration (IC50) incubated with 659 
dipeptidyl peptidase IV (DPP-IV) and GP-pNA for 30 min at 37C in Tris-HCl buffer pH 8.0. 660 
peptide_std: peptide which was not incubated with DPP-IV; GPpNA_blank: GP-pNA incubated 661 
with DPP-IV; peptides are abbreviated with the one letter amino acid code. 662 
 663 
Figure 3. Lineweaver and Burk double reciprocal plots for dipeptidyl peptidase IV (DPP-IV) 664 
inhibition with (A) ILDKVGINY (mixed-type), (B) ILELA (competitive), (C) LLQLEAIR 665 
(competitive) and (D) SPVVPF (mixed-type) evaluated at concentrations corresponding to their 666 
IC50 divided by 8, 16 and 40. Each point is the mean  SD (n=4). 667 
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